

Smoking Cessation Therapy is a Cost-Effective Intervention to Avoid Tooth Loss in Subjects With Periodontitis – An Economic Evaluation

Maria Luisa Silveira Souto

Universidade de São Paulo

Fernanda Campos Almeida Carrer

Universidade de São Paulo

Mariana Minatel Braga

Universidade de São Paulo

Cláudio Mendes Pannuti (✉ pannuti@usp.br)

Universidade de São Paulo

Research Article

Keywords: Cigarette Smoking, Smoking Cessation, Periodontitis, Health Economics, Modelling

Posted Date: February 23rd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-228724/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

25 **Background:** Smokers present a higher prevalence and severity of periodontitis and,
26 consequently, higher prevalence of tooth loss. Smoking cessation improves the
27 response to periodontal treatment and reduces tooth loss. So, the aim of this study was
28 evaluated the efficiency in resources allocation when implementing smoking cessation
29 therapy vs. its non-implementation in smokers with periodontitis.

30 **Methods:** We adopted the Brazilian public system perspective to determine the
31 incremental cost-effectiveness (cost per tooth loss avoided) and cost-utility (cost per
32 oral-related quality-adjusted life-year ([QALY] gained) of implementing smoking
33 cessation therapy. Base-case was defined as a 48 years-old male subject and horizon of
34 30 years. Effects and costs were combined in a decision analytic modeling framework
35 to permit a quantitative approach aiming to estimate the value of the consequences of
36 smoking cessation therapy adjusted for their probability of occurrence. Markov models
37 were carried over annual cycles. Sensitivity analysis tested methodological
38 assumptions.

39 **Results:** Implementation of smoking cessation therapy had an average incremental cost
40 of US\$60.58 per tooth loss avoided and US\$4.55 per oral related-QALY gained.
41 Considering uncertainties, the therapy could be cost-effective in the most part of
42 simulated cases, even being cheaper and more effective in 53% of cases in which the
43 oral-health related outcome is used as effect. Considering a willingness-to-pay of
44 US\$100 per health effect, smoking cessation therapy was cost-effective, respectively,
45 in 81% and 100% of cases in cost-utility and cost-effectiveness analyses.

46 **Conclusions:** Implementation of smoking cessation therapy may be cost-effective,
47 considering the avoidance of tooth loss and oral health-related consequences to patients.

48

49 **Keywords:** Cigarette Smoking; Smoking Cessation; Periodontitis; Health Economics,
50 Modelling

51

52 **BACKGROUND**

53

54 Cigarette smoking is a global public health problem associated with high
55 morbidity and mortality [1]. It is a major risk factor for health problems, such as cancer,
56 cardiovascular and respiratory diseases. Besides, smoking is a risk factor for oral
57 diseases, such as oral cancer, periodontitis, gingival recession, tooth loss and implant
58 failure [2-4]. Smoking is also associated with higher costs in periodontal treatment [5-
59 7] and increases the cost of life-time periodontal treatment from 8.8% up to 71.4% [7].

60 There is overwhelming evidence about the benefits of smoking cessation to the
61 general health [8, 9]. Quitting smoking also improves oral health conditions [4] . Two
62 interventional studies observed greater probing depth reduction and clinical attachment
63 gain in periodontitis patients that quit smoking, when compared to non-quitters [10,
64 11]. Moreover, observational studies have shown that former smokers lose fewer teeth
65 than current smokers [12, 13]. Therefore, smoking cessation therapy (SCT) should be
66 considered an important component of periodontal treatment [14].

67 Medical literature demonstrated that SCT is cost-effective because it reduces
68 health care expenditures associated with health effects of smoking [15, 16]. Although
69 there are some economic evaluations of periodontal [17-20], so far, this is the first study
70 that evaluated the cost-effectiveness of implementation of smoking cessation therapy
71 for periodontitis patients. Our hypothesis was that SCT could be a cost-effective
72 intervention because it reduces the risk of tooth loss and, consequently, it reduces the
73 costs associated with therapies aimed to replace teeth (prosthesis and implants). Such

74 appraisal could be extremely relevant in decision-making since smoking cessation
75 therapy is available in the Brazilian public health system (PHS), but is underused by
76 dentists. Therefore, the aim of this study was to evaluate the efficiency in resources
77 allocation when implementing smoking cessation therapy (SCT) vs. its non-
78 implementation in smokers with periodontitis that received periodontal treatment to
79 prevent tooth loss, in the context of the Brazilian PHS.

80

81 **METHODS**

82

83 This economic evaluation has been prepared according to the Consolidated
84 Health Economic Evaluation Reporting Standards (CHEERS) [21].

85

86 **Setting and Model**

87

88 This study describes a decision analytic model considering a male Brazilian
89 subject, age of 48 years-old and life expectancy of 28 years [22] as the base-case. In
90 this model, subjects are tobacco smokers with high level of dependence (>10 cigarettes
91 per day), with 20 teeth and generalized periodontitis stage III, grade C [23, 24]. Age
92 and number of remaining teeth were based on a previous study from our group, which
93 evaluated the effect of smoking cessation in periodontitis patients in a reference center
94 for smoking cessation in Brazil [25].

95 The study was conducted from the Brazilian PHS perspective. Data was
96 modeled using a Markov simulation model. Tree Age Pro 2017 (TreeAge Software,
97 Williamstown, MA, USA) was used for data modeling and analysis.

98

99 **Comparators**

100

101 A decision analytic modeling framework was constructed to estimate the
102 efficiency in resource allocation when implementing SCT in smoker patients with
103 periodontitis that received periodontal treatment to prevent tooth loss. This structure
104 was used to permit a quantitative approach to that would estimate the value of the
105 consequences of SCT adjusted for their probability of occurrence (Supplementary file
106 1).

107 Subjects entering the model were smokers with periodontitis. Some subjects
108 were supposed to receive SCT and others not. In both cases, they could stop smoking
109 or not. All subjects received non-surgical periodontal treatment (six sessions of scaling
110 and root planning) and one session of maintenance therapy (one session of scaling and
111 root planning). In the decision-analytic modeling framework, this stage was represented
112 as a simple decision tree. No possibility of relapsing smoking and/or need of
113 reintervention with SCT was considered.

114 In the Markov models, at each cycle, we considered that patients could transit
115 among possible health statuses. Thus, after initial treatment, at the end of each year
116 (cycle), subjects with periodontitis could transit between three states: 1) to stay in
117 maintenance therapy with no tooth loss, 2) to lose a tooth and not receive rehabilitation
118 or 3) to lose a tooth and receive prosthesis rehabilitation. When a tooth loss occurred,
119 we assumed that the remaining teeth would continue to receive periodontal
120 maintenance therapy (Figure 1; Supplementary File 1). As in a previous paper [7], we
121 assumed that current smokers would require two extra sessions of maintenance therapy.
122 Further, we assumed that quitters would present better response to periodontal therapy
123 [25]. To avoid clustering effect, only one tooth per patient was simulated.

124

125 **Time Horizon**

126

127 The life expectancy of a 48 years-old Brazilian male is 28 years [22].

128 Therefore, the time horizon of the analysis was set at 30 years.

129

130 **Discount rate**

131

132 In order to adjust time preference, costs and benefits were adjusted. A discount
133 rate of 5% for costs was considered in this model in accordance with Brazilian
134 guidelines [26].

135

136 **Modeled parameters**

137

138 Transition probabilities were defined by data from previous published studies.
139 Since we used annual cycles in the model, if a previous published study used a different
140 time frame (e.g., 10 years), we converted this probability in a 1-year value (Table 1)

141 The probabilities of quitting smoking with SCT after one year were based in a
142 study conducted in Brazil that found a probability of 30% of cessation after one year
143 [27]. The probability of quitting smoking without any therapy was 7% [28].

144 Probability of tooth loss during maintenance therapy was calculated using risk
145 ratios of tooth loss in current and former smokers, according to the expression below:

146

147
$$p = RR_{\text{tooth loss}} * X p_{\text{tooth loss non-smokers}}$$

148

149 In our model, when the tooth was lost, the subject could receive rehabilitation
150 with partial prosthesis or could not receive any rehabilitation. This probability was
151 based on a population-based survey about dental conditions of the State of São Paulo,
152 Brazil [29].

153

154 **Health Effects**

155

156 Cost-effectiveness analysis (CEA) was conducted considering the presence of
157 the tooth (maintenance therapy) as treatment success and tooth loss as failure,
158 regardless of prosthetic rehabilitation or not.

159 Cost-utility analysis (CUA) was performed combining utility values with time
160 spent in state of health, resulting in number of quality-adjusted life years (QALY) [30].
161 Determination of the utilities was conducted through a conversion of Oral Health
162 Impact Profile (OHIP) scores [31, 32]. OHIP scores, selected from studies with
163 Brazilian subjects, were converted to a continuous value from 0 to 1 (0: lowest score
164 corresponding to the worst oral health state imaginable; 1: highest score corresponding
165 to the best oral health state imaginable). We assumed a linear relationship between
166 OHIP scores and the oral-health related utility scores obtained. Utility scores with
167 corresponding OHIP score and data source are shown in Supplementary File 02.

168

169 **Outcomes**

170

171 Incremental costs (Δcost) and incremental effects (Δeffect) were calculated
172 based on the fact that incremental cost per health effect could be estimated to determine

173 the differences both in costs and in the effects of implementation of SCT, over non-
174 implementation.

175

176 **Costs and Resources**

177

178 We used costs from the Brazilian public service. We considered only direct
179 costs of the procedures (Table 2) and the need of one cycle of SCT. Possible relapses
180 and need of repetition of SCT were not explored in this study.

181 SCT adopted in the Brazilian public health system consists in cognitive-
182 behavioral therapy, nicotine replacement therapy (transdermal patches 7, 14 or 21mg
183 and gums 2 or 4mg) and bupropion hydrochloride 150mg. Brief counseling is
184 conducted during the routine consultations. The therapy is conducted by doctors, nurses
185 and psychologists, in specialized centers. Brazilian SCT model consists in four weekly
186 sessions in the first month and 12 sessions until the completion of one year of treatment.
187 Direct costs were based on a trial conducted in Brazil [33]. Costs with professional
188 training for SCT were not considered in the primary model, but they were modeled in
189 the sensitivity analysis. In the Brazilian public service, periodontal treatment,
190 maintenance therapy and prosthetic rehabilitation are conducted in Dental Specialty
191 Centers (CEOs). We chose partial removable prosthesis as the type of prosthetic
192 rehabilitation in our model because partial fixed prosthesis is not performed in the
193 Brazilian PHS. Moreover, the option for implant therapy was modeled in the sensitivity
194 analysis. This therapy is performed only in some CEOs, in some Brazilian cities, and
195 in a reduced number when compared with partial removable prosthesis.

196 Costs of periodontal procedures, prosthetic rehabilitation and implant therapy
197 were calculated considering the hourly wages of the dentist in Dental Specialty Centers
198 (CEOs) [34], PHS unified table and medications costs (BPS- Health Price Bank) [35].

199 All costs from years prior to 2020 were adjusted for inflation using the National
200 Consumer Price (<https://www.bcb.gov.br/acessoinformacao/calculadoradocidadao>).

201 The conversion into purchasing power parity (ppp) was based on The International
202 Monetary Fund considering 1.00 US dollar as R\$ 2.46
203 (<https://www.imf.org/external/datamapper/PPPEX@WEO/OEMDC/ADVEC/WEO>
204 WORLD).

205

206 **Sensitivity analysis**

207 Deterministic and probabilistic sensitivity analyses were conducted
208 considering the figures shown on Table 3. Time horizon and model settings were
209 kept constant.

210

211 Deterministic Sensitivity Analysis

212

213 We varied SCT costs to cover different scenarios, such as different protocols.
214 The costs used in this analysis were based on the costs presented by Mendes et al.
215 (2016) [33]. Professional's training was considered in a separate analysis as a global
216 cost for SCT program maintenance (Table 3).

217 The projected costs of the items of periodontal treatment, maintenance therapy
218 and no rehabilitation were varied in 10%.

219 Discount rate was analyzed ranging from 3% to 7%. Probability of annual tooth
220 loss in non-smokers varied between probabilities from studies with Brazilian subjects
221 [36, 37]. Probability of losing a tooth and not receiving rehabilitation varied, with the
222 insertion of a higher probability of any rehabilitation [38].

223 To observe the influence of the rehabilitation with implant therapy, the cost and
224 utility of this therapy were inserted in the model in the condition of subjects that lose a
225 tooth and received rehabilitation (Table 02).

226 Utility scores varied using the standard deviation of the mean scores.

227

228 Probabilistic Sensitivity Analysis

229

230 Distribution of variables that could interfere in the model and their respective
231 distributions were inserted in the probabilistic sensitivity analysis (Table 3). Monte
232 Carlo simulations repeated 1000 times were plotted on the cost-effectiveness plane for
233 both analysis (CEA and CUA).

234 Probability of tooth loss in smokers and non-smokers varied using the natural
235 logarithm of the confidence intervals (CI) of the risk ratios of tooth loss in former and
236 current smokers.

237 Probability of losing a tooth and not receiving rehabilitation varied between the
238 average of CI of this probability.

239

240 Analysis of uncertainty and Cost-Acceptability curves

241

242 All stochastic model input parameters were expressed using probability
243 distributions derived primarily from the selected studies (Table 1). Modeling

244 assumptions were varied through a series of deterministic sensitivity analyses on the
245 probabilistic model. The assumed probability distributions used for each stochastic
246 model input parameter are presented in Table 3. Normal distributions were assumed for
247 risk of tooth loss, triangular distributions were used for cost and utility variables and
248 uniform distribution was used in the discount rate.

249 In probabilistic analysis, we used Monte Carlo simulation techniques with 1,000
250 trials for each separate run of the model. Average costs, effects, cost-effectiveness, and
251 cost-utility results were based on means of the simulated results. These results were
252 plotted in a cost-effectiveness plane, presenting information on the joint distribution of
253 incremental cost and incremental effectiveness. Therefore, probabilities of combining
254 outcomes (risks and benefits) in different quadrants could be explored.

255 In Brazilian guidelines for health technology assessments, there is not a
256 threshold to determine whether an intervention is cost-effective or not. Additionally,
257 we considered health effects whose potential willingness to pay (WTP) were not
258 known. This is the reason why Cost-Effectiveness Acceptability Curves (CEAC) were
259 plotted supposing different hypothetical values for WTP thresholds.

260

261 **RESULTS**

262

263 **Incremental Costs and Effects**

264

265 In both analyses, when the base-case was assumed, implementation of smoking
266 cessation therapy was dominant (less costly and more effective) over non-
267 implementation (Table 4). Implementing the therapy saved approximately US\$ 100
268 over the time horizon accompanied by slight better effect, both in CEA and CUA.

269

270 **Sensitivity analyses and characterization of uncertainty**

271 The majority of the parameters tested in sensitivity analyses did not impact on
272 the results and smoking cessation therapies remained a cost-effective option despite
273 varying some model assumptions. When the cost of SCT was varied to cover different
274 scenarios, implementation of the therapy was also not dominant over non-
275 implementation for some of them (Figure 2). For the maximum scenario, expenses for
276 implementing SCT were observed ($\Delta\text{cost}=\text{US}\201). In this case, incremental costs of
277 US\$ 403 per tooth loss avoided and US\$ 347 per oral-QALY gained were calculated.

278 Importantly, even when implant therapy was used to rehabilitate patients with
279 tooth loss, implementation of SCT remained cost-effective and non-implementation of
280 SCT was dominated by the implementation. Other assumptions did not influence on
281 previous trends.

282 When considering the uncertainties, implementation of SCT tended to be more
283 costly and more effective in the great majority of the simulated cases to the CEA
284 (99.9%). In the CUA, 53% of the simulated cases were in the dominant quadrant
285 (Figure 2). Besides, approximately 53% of the cases would be in the northeast quadrant,
286 being maximum incremental cost as high as approximately US\$300 associated to
287 incremental oral-related QALY gained ranging from 0 to 2.5 (Figure 2 and
288 Supplementary file 3)

289 CEACs demonstrated that SCT implementation, at a hypothetical WTP of US\$
290 100, is considered as the optimal strategy in 100% of cases, when concerning to tooth
291 loss (Figure 3). When QALYs were considered for the analyses, at the same
292 hypothetical WTP, 81% of the iterations were cost-effective (Figure 3). Considering
293 the last situation, 98% of cost-effective iterations were observed at a WTP=US\$500.

294

295 **DISCUSSION**

296

297 The results of this study show that implementation of SCT is an efficient way
298 of allocating resources compared to its non-implementation, in the perspective of the
299 Brazilian PHS. Even considering additional costs related to cognitive-behavioral
300 intervention for smoking cessation, they tended to be favorably balanced by the health
301 gain achieved. In some circumstances, the initial extra expenses in implementing the
302 SCT may either be compensated by costs saved in the subsequent dental treatment for
303 smokers.

304 We chose the PHS perspective because all Brazilian citizens are entitled to the
305 services provided by the public system [39]. Currently, SCT in the PHS is conducted
306 by a multi-professional team that does not include dentists. However, this intervention
307 could be delivered by dentists in the Brazilian PHS [40], especially if one considers that
308 SCT conducted by oral health professionals increases tobacco abstinence rates [41].

309 The cost-effectiveness of smoking on periodontal therapy in private practice
310 was evaluated by Fardal et al. (2018) [7], based on costs of the American Dental
311 Association. They found an increased cost of periodontal treatment for smokers and
312 that the lifetime cost of periodontal therapy is equivalent to about 25% of the cost of
313 smoking for patients who smoke 20 cigarettes per day. However, the cost-effectiveness
314 of SCT was not evaluated. Feldman et al. (2019) [42] compared the cost-effectiveness
315 of a high-intensity therapy with a low-intensity smoking cessation intervention in a
316 Swedish dental setting. Their results favored the high-intensity smoking cessation
317 intervention when willingness to pay was €4000/QALY. The utility weights derived
318 via general health-related quality of life questionnaire. Their results are important

319 because this high-intensity smoking cessation intervention is very similar to SCT
320 adopted in Brazilian PHS. According to their findings and our results, SCT is a cost-
321 effective intervention for periodontitis patients, which empathizes the necessity to
322 increase application of SCT in the Brazilian PHS dental setting. SCT is can be
323 performed by dentists and it is currently underused in Brazil.

324 From the Brazilian PHS perspective, SCT could be considered a cost-effective
325 option (probability from 81-99% excluding the uncertainties) even considering a low
326 WTP threshold (US\$). Even when uncertainties are considered, we could observe that
327 a low incremental cost (not exceeding US\$300) could be expected. As for the health
328 effects considered as outcomes in the present evaluations, we do not have a known
329 WTP. We analyzed the CEA and the probabilities of simulated cases yield on different
330 quadrants as a manner of permitting the decision-maker to judge this information and
331 consider if it is acceptable. It is possible to opt for the different preferences for
332 inefficiencies occurring in different quadrants since both size and nature of risks may
333 be presented [43].

334 Although in both analysis, CEA and CUA, the implementation of SCT was cost-
335 effective, the health effects in CUA were smaller than in CEA. This result was expected
336 because effects in subjective measures are less evident than in objective measures.

337 We chose tooth loss as the outcome of CEA because it is considered the true
338 endpoint of periodontal disease [44, 45]. It is the most important objective outcome to
339 the patient and therefore it might be considered the most appropriate outcome in an
340 economic analysis [30]. Some of the published studies used surrogate outcomes, such
341 as bleeding on probing, plaque index, probing depth reduction and clinical attachment
342 gain [46 – 48]. However, the precise impact of these surrogate outcomes on the patient
343 is unclear [30].

344 We included a CUA in our study, because this type of analysis allows including
345 a measure of the patients' preferences and perception about their health. The
346 importance of patient related outcomes is impacting in more studies with CUA in
347 dentistry [49]. However, there is still a scarcity of this type of analysis in some regions,
348 such as in South American countries [49]. Medical literature usually uses EuroQOL-
349 5Dimension (EQ-5D) [50] or Structured Form 6 Dimension (SF-6D) [51] to
350 determinate QALY. However, these instruments evaluate general health, which is
351 unlikely to be sensitive to important domains of oral health, such as chewing ability or
352 aesthetics [52]. In the absence of a suitable measure in Dentistry, and considering the
353 low sensitivity of medical questionnaires, we assumed that the utility was proportional
354 to quality of life. This methodology was proposed by previous studies that converted
355 scores from quality of life questionnaires to utilities scores between 0 and 1 and
356 reflected changes related to periodontal conditions/treatment [53, 54]. Even though this
357 is not the ideal approach, the use of this interim tool allowed the incorporation of a
358 patient-centered approach into the analysis. We believe that these limitations do not
359 impact on our findings because the utility scores were used in both strategies that were
360 analyzed.

361 The inclusion of CUA also allows verifying that there are situations in which
362 SCT could be cost-saving compared to its non-implementation, what is an additional
363 argument to endorse this therapy in the PHS. On the other hand, our CUA should be
364 carefully interpreted, because it is not possible to affirm that quality of life has a linear
365 relationship with utility. We expect that the use oral health-related quality of life
366 instruments may have registered oral health conditions that are be important to the
367 patient, which are not necessarily comparable to general health status. On the other
368 hand, the implicit limitations under this interim assumption should be considered when

369 comparing to QALYs reported in other studies for making decisions based on that. Oral
370 health-specific utility measures will be more sensitive in capturing the effectiveness of
371 oral health interventions [49]. Instruments that use an indexed scale for oral health-
372 related aspects need to be developed in order to improve the comparison between
373 studies and different therapies.

374 We applied sensitivity analysis to characterize the uncertainty of our results. We
375 tested a model with implants because this type of rehabilitation presents better utility
376 scores than partial prosthesis, but it also includes higher costs in the model. However,
377 even considering these higher costs, rehabilitation with implants did not affect the
378 results and the implementation of SCT remained a cost-effective therapy. Further, it
379 was dominant over the non-implementation of SCT. Partial fixed prostheses were not
380 tested in our models since they are not available in the Brazilian PHS. Moreover, they
381 may result in additional harms such as pulp exposure, which may lead to endodontic
382 treatment [19].

383 Different scenarios, considering differential use of resources in SCT [33] were
384 considered when the SCT costs were varied in sensitivity analysis. A marginal
385 dominance was observed, since when varying the SCT costs, the therapy remained cost-
386 effective (but not dominant, as in the base-case). These findings also provide evidence
387 that SCT should be implemented for PHS. Since the cognitive-behavioral therapy is
388 responsible for the majority of the SCT costs, we believe the variation in SCT costs
389 considering these different scenarios may also reflect possible variations proposed in
390 different protocols for SCT, even those different from Brazil. Although the costs for
391 professional training were not included in the primary model, even under a conservative
392 approach, considering the implementation of a new strategy in the PHS, these additional
393 costs did not impact on present results.

394 The number of sessions of cognitive-behavioral therapy in SCT seems to exert
395 the same influence on cost-effectiveness of the therapy. The number and frequency of
396 periodontal maintenance sessions can vary according to clinical conditions, such as
397 extension and severity of the disease. The number of SCT sessions was fixed, as in the
398 Brazilian protocol for SCT, but different scenarios were used in the sensitivity analyses
399 to explore these possible variations. Even when we tested variations in SCT costs, the
400 implementation of SCT remained cost-effective. Therefore, despite exploring possible
401 variables and uncertainties related to our models for CEA and CUA, we reinforce that
402 the SCT may be a cost-effective therapy for periodontitis patients to be implemented in
403 the Brazilian PHS.

404 Economic evaluations are a standard tool in the assessment of health care
405 technologies in order to maximize benefits from the available resources [55]. The need
406 to allocate public finances increased the interest in cost-effectiveness research in
407 dentistry [56]. A cost-effectiveness criterion can play an important role by guiding the
408 incorporation of new technologies into the population. Policymakers from some
409 countries, such as Australia, Canada and European countries, have adopted economic
410 evaluations to their drug guidelines and reimbursement [57]. The present findings are
411 especially important for the Brazilian PHS and demonstrate that SCT should be
412 implemented. It is necessary to emphasize that studies with different populations, costs
413 and perspectives should be conducted to confirm the cost-effectiveness of the
414 implementation of SCT in relation to tooth loss in different scenarios. This model can
415 be used as a model to future cost-effectiveness analysis with costs and effects from
416 other countries. As we adopted a model in which repetitions of SCT were not included
417 due to smoking relapse, other models may also test the influence of variables related to
418 that in the cost-effectiveness of SCT.

419

420 **CONCLUSIONS**

421

422 Implementation of SCT in periodontitis patients from the Brazilian public
423 health system (PHS) is a more efficient way of allocating resources compared to its
424 non-implementation, possibly to be cost-saving in some circumstances both when
425 considering tooth loss or oral health-related QALY gains.

426 **Abbreviations**

427 SCT: smoking cessation therapy; CHEERS: Consolidated Health Economic Evaluation
428 Reporting Standards; PHS: Brazilian public health system; CEA: cost-effectiveness
429 analysis; CUA: cost-utility analysis; QALY: quality-adjusted life years; OHIP: Oral
430 Health Impact Profile; CEOs: Dental Specialty Centers; ppp: purchasing power parity;
431 WTP: potential willingness to pay; CEAC: Cost-Effectiveness Acceptability Curves

432

433 **DECLARATIONS**

434 **Acknowledgements**

435 None.

436 **Availability of data and materials**

437 All data generated or analyzed during this study are included within the article (and
438 its additional files).

439 **Authors' contribution**

440

441 MLSS: formulated the decision tree and bubble diagram, collected probabilities used
442 in the Markov model, collected costs, elaborated tables, wrote the manuscript and
443 submitted the manuscript; FCAC: collected PHS costs and contributed to write the
444 manuscript; MMB: performed the economic analysis, contributed to formulate the
445 decision tree and bubble diagram, elaborated figures and contributed to write the
446 manuscript; CMP: contributed to formulate the decision tree and bubble diagram,
447 contributed to write the final version of the manuscript. All authors read and approved
448 the final version of the manuscript.

449 **Ethics approval and consent to participate**

450 Not applicable.

451 **Consent for publication**

452 Not applicable.

453 **Competing interests**

454 The authors declare that they have no competing interests.

455 This study was financed in part by the Coordenação de Aperfeiçoamento Pessoal de
456 Nível Superior – Brasil (CAPES) – Finance Code 001

457

458 **REFERENCES**

459

- 460 1. World Health Organization. WHO report on the global tobacco epidemic 2017.
461 2017. Available from: https://www.who.int/tobacco/global_report/2017/en/
462
- 463 2. Chrcanovic BR, Albrektsson T, Wennerberg A. Smoking and dental implants:
464 A systematic review and meta-analysis. *J Dent*. 2015 May;43(5):487-98.
465
- 466 3. Corraini P, Baelum V, Pannuti CM, Pustiglioni AN, Romito GA, Pustiglioni
467 FE. Periodontal attachment loss in an untreated isolated population of Brazil. *J*
468 *Periodontol*. 2008 Apr;79(4):610-20.
469
- 470 4. Warnakulasuriya S, Dietrich T, Bornstein MM, Casals Peidró E, Preshaw PM,
471 Walter C, Wennström JL, Bergström J. Oral health risks of tobacco use and
472 effects of cessation. *Int Dent J*. 2010 Feb;60(1):7-30.
473
- 474 5. Ide R, Hoshuyama T, Wilson D, Takahashi K, Higashi T. The effects of
475 smoking on dental care utilization and its costs in Japan. *J Dent Res*. 2009
476 Jan;88(1):66-70.
477
- 478 6. Park YD, Kang JO, Kim SJ, Kwon HJ, Hwang JH, Hwang KS. Estimation of
479 the costs of smoking-related oral disease: a representative South Korean study.
480 *Int Dent J*. 2012 Oct;62(5):256-61.
481
- 482 7. Fardal Ø, Grytten J, Martin J, Ellingsen S, Fardal P, Heasman P, Linden GJ.
483 Adding smoking to the Fardal model of cost-effectiveness for the lifetime
484 treatment of periodontal diseases. *J Periodontol*. 2018 Nov;89(11):1283-1289.
485
- 486 8. Bai JW, Chen XX, Liu S, Yu L, Xu JF. Smoking cessation affects the natural
487 history of COPD. *Int J Chron Obstruct Pulmon Dis*. 2017 Nov 16;12:3323-
488 3328.
489
- 490 9. Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN,
491 McAfee T, Peto R. 21st-century hazards of smoking and benefits of cessation
492 in the United States. *N Engl J Med*. 2013 Jan 24;368(4):341-50.
493

- 494 10. Preshaw PM, Heasman L, Stacey F, Steen N, McCracken GI, Heasman PA. The
495 effect of quitting smoking on chronic periodontitis. *J Clin Periodontol*. 2005
496 Aug;32(8):869-79.
497
- 498 11. Rosa EF, Corraini P, de Carvalho VF, Inoue G, Gomes EF, Lotufo JP, De
499 Micheli G, Pannuti CM. A prospective 12-month study of the effect of smoking
500 cessation on periodontal clinical parameters. *J Clin Periodontol*. 2011
501 Jun;38(6):562-71.
502
- 503 12. Dietrich T, Walter C, Oluwagbemigun K, Bergmann M, Pischon T, Pischon N,
504 Boeing H. Smoking, Smoking Cessation, and Risk of Tooth Loss: The EPIC-
505 Potsdam Study. *J Dent Res*. 2015 Oct;94(10):1369-75.
506
- 507 13. Krall EA, Dietrich T, Nunn ME, Garcia RI. Risk of tooth loss after cigarette
508 smoking cessation. *Prev Chronic Dis*. 2006 Oct;3(4):A115.
509
- 510 14. Leite FRM, Nascimento GG, Scheutz F, López R. Effect of Smoking on
511 Periodontitis: A Systematic Review and Meta-regression. *Am J Prev Med*. 2018
512 Jun;54(6):831-841.
513
- 514 15. Kahende JW, Loomis BR, Adhikari B, Marshall L. A review of economic
515 evaluations of tobacco control programs. *Int J Environ Res Public Health*. 2009
516 Jan;6(1):51-68.
517
- 518 16. Ruger JP, Lazar CM. Economic evaluation of pharmaco- and behavioral
519 therapies for smoking cessation: a critical and systematic review of empirical
520 research. *Annu Rev Public Health*. 2012 Apr;33:279-305.
521
- 522 17. Gaunt F, Devine M, Pennington M, Vernazza C, Gwynnett E, Steen N,
523 Heasman P. The cost-effectiveness of supportive periodontal care for patients
524 with chronic periodontitis. *J Clin Periodontol*. 2008 Sep;35(8 Suppl):67-82.
525
- 526 18. Pennington M, Heasman P, Gaunt F, Güntsch A, Ivanovski S, Imazato S,
527 Rajapakse S, Allen E, Flemmig T, Sanz M, Vernazza C. The cost-effectiveness

- 528 of supportive periodontal care: a global perspective. *J Clin Periodontol.* 2011
529 Jun;38(6):553-61.
- 530
- 531 19. Schwendicke F, Stolpe M, Plaumann A, Graetz C. Cost-effectiveness of regular
532 versus irregular supportive periodontal therapy or tooth removal. *J Clin*
533 *Periodontol.* 2016 Nov;43(11):940-947.
- 534
- 535 20. Solowiej-Wedderburn J, Ide M, Pennington M. Cost-effectiveness of non-
536 surgical periodontal therapy for patients with type 2 diabetes in the UK. *J Clin*
537 *Periodontol.* 2017 Jul;44(7):700-707.
- 538
- 539 21. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D,
540 Augustovski F, Briggs AH, Mauskopf J, Loder E; CHEERS Task Force.
541 Consolidated Health Economic Evaluation Reporting Standards (CHEERS)
542 statement. *BMJ.* 2013 Mar 25;346:f1049.
- 543
- 544 22. IBGE. Tábuas Completas de Mortalidade. 2017. Available from:
545 [https://www.ibge.gov.br/estatisticas/sociais/populacao/9126-tabuas-](https://www.ibge.gov.br/estatisticas/sociais/populacao/9126-tabuas-completas-de-mortalidade.html?&t=downloads)
546 [completas-de-mortalidade.html?&t=downloads.](https://www.ibge.gov.br/estatisticas/sociais/populacao/9126-tabuas-completas-de-mortalidade.html?&t=downloads)
- 547
- 548 23. Caton JG, Armitage G, Berglundh T, Chapple ILC, Jepsen S, Kornman KS,
549 Mealey BL, Papapanou PN, Sanz M, Tonetti MS. A new classification scheme
550 for periodontal and peri-implant diseases and conditions - Introduction and key
551 changes from the 1999 classification. *J Clin Periodontol.* 2018 Jun;45 Suppl
552 20:S1-S8.
- 553
- 554 24. Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis:
555 Framework and proposal of a new classification and case definition. *J Clin*
556 *Periodontol.* 2018 Jun;45 Suppl 20:S149-S161. doi: 10.1111/jcpe.12945.
557 Erratum in: *J Clin Periodontol.* 2019 Jul;46(7):787.
- 558

- 559 25. Rosa EF, Corraini P, Inoue G, Gomes EF, Guglielmetti MR, Sanda SR, Lotufo
560 JP, Romito GA, Pannuti CM. Effect of smoking cessation on non-surgical
561 periodontal therapy: results after 24 months. *J Clin Periodontol*. 2014
562 Dec;41(12):1145-53.
563
- 564 26. Brasil. Ministério da Saúde. Secretaria de Ciência T e IED de C e T. Diretrizes
565 metodológicas: diretriz de avaliação econômica. 2014. Available from:
566 bvsms.saude.gov.br/bvs/publicacoes/diretrizes_metodologicas_diretriz_avaliao_economica.pdf
567
568
- 569 27. Prado GF, Lombardi EM, Bussacos MA, Arrabal-Fernandes FL, Terra-Filho M,
570 Santos Ude P. A real-life study of the effectiveness of different pharmacological
571 approaches to the treatment of smoking cessation: re-discussing the predictors
572 of success. *Clinics (Sao Paulo)*. 2011;66(1):65-71.
573
574
- 575 28. Zhu S, Melcer T, Sun J, Rosbrook B, Pierce JP. Smoking cessation with and
576 without assistance: a population-based analysis. *Am J Prev Med*. 2000
577 May;18(4):305-11.
578
- 579 29. Pereira, A. C., Vieira, V., & Frias, A. C. 2016. *SB São Paulo Pesquisa Estadual*
580 *de Saúde Bucal*. Águas de São Pedro.
581
- 582 30. Vernazza C, Heasman P, Gaunt F, Pennington M. How to measure the cost-
583 effectiveness of periodontal treatments. *Periodontol 2000*. 2012 Oct;60(1):138-
584 46.
585
- 586 31. Slade GD, Spencer AJ. Development and evaluation of the Oral Health Impact
587 Profile. *Community Dent Health*. 1994 Mar;11(1):3-11.
588

589

590 32. Pires CP, Ferraz MB, de Abreu MH. Translation into Brazilian Portuguese,
591 cultural adaptation and validation of the oral health impact profile (OHIP-49).
592 Braz Oral Res. 2006 Jul-Sep;20(3):263-8.

593

594 33. Mendes AC, Toscano CM, Barcellos RM, Ribeiro AL, Ritzel JB, Cunha VS,
595 Duncan BB. Costs of the Smoking Cessation Program in Brazil. Rev Saude
596 Publica. 2016 Nov 10;50(0):66.

597

598 34. de Oliveira RS, de Moraes HMM, de Goes PSA, Botazzo C, Magalhães BG
599 Relações contratuais e perfil dos cirurgiões dentistas em centros de
600 especialidades odontológicas de baixo e alto desempenho no Brasil. Saude e
601 Sociedade. 2015 24, 792–802

602

603 35. Brasil. Ministério da Saúde. Banco de Preços em Saúde. 2017. Availabe from:
604 [http://portalms.saude.gov.br/gestao-do-sus/economia-da-saude/banco-de-](http://portalms.saude.gov.br/gestao-do-sus/economia-da-saude/banco-de-precos-em-saude)
605 [precos-em-saude](http://portalms.saude.gov.br/gestao-do-sus/economia-da-saude/banco-de-precos-em-saude)

606

607 36. Chambrone LA, Chambrone L. Tooth loss in well-maintained patients with
608 chronic periodontitis during long-term supportive therapy in Brazil. J Clin
609 Periodontol. 2006 Oct;33(10):759-64.

610

611 37. Stadler AF, Mendez M, Oppermann RV, Gomes SC. Tooth Loss in Patients
612 under Periodontal Maintenance in a Private Practice: A Retrospective Study.
613 Braz Dent J. 2017 Jul-Aug;28(4):440-446.

614

615 38. Brasil. Ministério da Saúde. SB Brasil 2010: Pesquisa Nacional de Saúde Bucal:
616 resultados principais. 2012. Available from: <https://doi.org/10.3310/hta21210>

617

- 618 39. Castro MC, Massuda A, Almeida G, Menezes-Filho NA, Andrade MV, de
619 Souza Noronha KVM, Rocha R, Macinko J, Hone T, Tasca R, Giovanella L,
620 Malik AM, Werneck H, Fachini LA, Atun R. Brazil's unified health system: the
621 first 30 years and prospects for the future. *Lancet*. 2019 Jul 27;394(10195):345-
622 356
623
- 624 40. Pucca GA Jr, Gabriel M, de Araujo ME, de Almeida FC. Ten Years of a
625 National Oral Health Policy in Brazil: Innovation, Boldness, and Numerous
626 Challenges. *J Dent Res*. 2015 Oct;94(10):1333-7.
627
- 628 41. Carr AB, Ebbert J. Interventions for tobacco cessation in the dental setting.
629 *Cochrane Database Syst Rev*. 2012 Jun 13;2012(6):CD005084.
630
- 631 42. Feldman I, Helgason AR, Johansson P, Tegelberg Å, Nohlert E. Cost-
632 effectiveness of a high-intensity versus a low-intensity smoking cessation
633 intervention in a dental setting: long-term follow-up. *BMJ Open*. 2019 Aug
634 15;9(8):e030934
635
- 636 43. Sendi P, Gafni A, Birch S. Opportunity costs and uncertainty in the economic
637 evaluation of health care interventions. *Health Econ*. 2002 Jan;11(1):23-31.
638
- 639 44. Hujoel PP, DeRouen TA. A survey of endpoint characteristics in periodontal
640 clinical trials published 1988-1992, and implications for future studies. *J Clin*
641 *Periodontol*. 1995 May;22(5):397-407.
642
- 643 45. Pannuti CM, Sendyk DI, Graças YTD, Takai SL, SabÓia VPA, Romito GA,
644 Mendes FM. Clinically relevant outcomes in dental clinical trials: challenges
645 and proposals. *Braz Oral Res*. 2020;34 Suppl 2:e073.
646
- 647 46. Listl S, Tu YK, Faggion CM Jr. A cost-effectiveness evaluation of enamel
648 matrix derivatives alone or in conjunction with regenerative devices in the
649 treatment of periodontal intra-osseous defects. *J Clin Periodontol*. 2010
650 Oct;37(10):920-7.
651

- 652 47. Jönsson B, Ohrn K, Lindberg P, Oscarson N. Cost-effectiveness of an
653 individually tailored oral health educational programme based on cognitive
654 behavioural strategies in non-surgical periodontal treatment. *J Clin Periodontol.*
655 2012 Jul;39(7):659-65.
656
657
- 658 48. Mohd-Dom TN, Wan-Puteh SE, Muhd-Nur A, Ayob R, Abdul-Manaf MR,
659 Abdul-Muttalib K, Aljunid SM. Cost-Effectiveness of Periodontitis
660 Management in Public Sector Specialist Periodontal Clinics: A Societal
661 Perspective Research in Malaysia. *Value Health Reg Issues.* 2014 May;3:117-
662 123.
663
- 664 49. Hettiarachchi RM, Kularatna S, Downes MJ, Byrnes J, Kroon J, Laloo R,
665 Johnson NW, Scuffham PA. The cost-effectiveness of oral health interventions:
666 A systematic review of cost-utility analyses. *Community Dent Oral Epidemiol.*
667 2018 Apr;46(2):118-124
668
- 669 50. Brooks R. EuroQol: the current state of play. *Health Policy.* 1996 Jul;37(1):53-
670 72.
671
- 672 51. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T,
673 Westlake L. Validating the SF-36 health survey questionnaire: new outcome
674 measure for primary care. *BMJ.* 1992 Jul 18;305(6846):160-4.
675
- 676 52. Stone SJ, McCracken GI, Heasman PA, Staines KS, Pennington M. Cost-
677 effectiveness of personalized plaque control for managing the gingival
678 manifestations of oral lichen planus: a randomized controlled study. *J Clin*
679 *Periodontol.* 2013 Sep;40(9):859-67.
680
- 681 53. Korenori A, Koji K, Yuki T, Murata T, Sachiko TM, Shunsuke B. Cost-
682 effectiveness of molar single-implant versus fixed dental prosthesis. *BMC Oral*
683 *Health.* 2018 Aug 20;18(1):141.
684

685 54. Mohd-Dom T. Quality-adjusted tooth years (QATY) as an outcome measure of
686 periodontal treatment. BMC Public Health. 2014; 14: P10. Doi: 10.1186/1471-
687 2458-14-s1-p10

688

689 55. Listl S, Grytten JI, Birch S. What is health economics? Community Dent Health.
690 2019 Nov 28;36(4):262-274.

691

692 56. Eow J, Duane B, Solaiman A, Hussain U, Lemasney N, Ang R, O'Kelly-Lynch
693 N, Girgis G, Collazo L, Johnston B. What evidence do economic evaluations in
694 dental care provide? A scoping review. Community Dent Health. 2019 May
695 30;36(2):118-125.

696

697 57. Neumann PJ, Johannesson M. From principle to public policy: using cost-
698 effectiveness analysis. Health Aff (Millwood). 1994 Summer;13(3):206-14.

699

700

701

702 **TABLES**

703 They were submitted as individual files.

704

705 Table 1: States and Probabilities used in the model

706

707 Table 2: Cost survey on several states

708

709 Table 3: States and Probabilities used in Sensitivity Analysis

710

711 Table 4: Incremental costs and effects for implementation of SCT over the non-

712 implementation of SCT

713

714 **FIGURE LEGENDS**

715

716 Figure 1: Bubble diagram: states and transitions used in the model

717

718 Figure 2: Cost-effectiveness planes considering as health effects (a) the avoidance or
719 prevention of tooth loss and (b) the oral-related quality-adjusted life-years. (P_{quadrant} :
720 probability of simulated points is found on that quadrant – NE: Northeast, NW:
721 Northwest, SE: Southeast; SW: southwest, PSA: Probabilistic Simulation Analysis).

722

723 Figure 3: Acceptability curves considering as health effects (a) the avoidance or
724 prevention of tooth loss and (b) the oral-related quality-adjusted life-years.

725

726 **SUPPLEMENTARY FILES**

727 Supplementary file 1: Decision tree

728

729 Supplementary file 2: Utility scores

730

731 Supplementary file 3: Expected costs, outcomes, cost-effectiveness, cost-utility based
732 on deterministic model by varying each variable from a minimum (green) to a
733 maximum (red) values

Figures




Figure 1

Bubble diagram: states and transitions used in the model




Figure 2

Cost-effectiveness planes considering as health effects (a) the avoidance or prevention of tooth loss and (b) the oral-related quality-adjusted life-years. (Pquadrant: probability of simulated points is found on that quadrant – NE: Northeast, NW: Northwest, SE: Southeast; SW: southwest, PSA: Probabilistic Simulation Analysis).




Figure 3

Acceptability curves considering as health effects (a) the avoidance or prevention of tooth loss and (b) the oral-related quality-adjusted life-years.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supplementaryfile1.pdf](#)
- [Supplementaryfile02.docx](#)
- [SupplememntaryFile03.docx](#)